Phase IIb formulation + Putative phase III formulation + Slow dissolution variant 1 + Slow dissolution variant 2 + Test treatment E
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Uncontrolled and Persistent Asthma
Conditions
Uncontrolled and Persistent Asthma
Trial Timeline
Jan 1, 2014 → Apr 1, 2014
NCT ID
NCT01989520About Phase IIb formulation + Putative phase III formulation + Slow dissolution variant 1 + Slow dissolution variant 2 + Test treatment E
Phase IIb formulation + Putative phase III formulation + Slow dissolution variant 1 + Slow dissolution variant 2 + Test treatment E is a phase 1 stage product being developed by AstraZeneca for Uncontrolled and Persistent Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT01989520. Target conditions include Uncontrolled and Persistent Asthma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01989520 | Phase 1 | Completed |
Competing Products
17 competing products in Uncontrolled and Persistent Asthma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KHK4563 + KHK4563 + KHK4563 + Placebo | Kyowa Kirin | Phase 2 | 52 |
| HR17031 injection + insulin glargine | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Baxdrostat + Placebo | AstraZeneca | Phase 3 | 77 |
| Tralokinumab | AstraZeneca | Phase 3 | 77 |
| Baxdrostat + Placebo | AstraZeneca | Phase 3 | 77 |
| Benralizumab | AstraZeneca | Phase 3 | 77 |
| Baxdrostat + Placebo | AstraZeneca | Phase 2 | 52 |
| Experimental: Tralokinumab | AstraZeneca | Phase 3 | 77 |
| CIN-107 + Placebo | AstraZeneca | Phase 2 | 52 |
| Pegloticase + Methotrexate (MTX) | Amgen | Approved | 84 |
| Pegloticase | Amgen | Approved | 84 |
| Pegloticase + Methotrexate | Amgen | Phase 3 | 76 |
| Pegloticase + Methotrexate (MTX) | Amgen | Approved | 84 |
| Pegloticase with MTX | Amgen | Approved | 84 |
| abrocitinib | Pfizer | Pre-clinical | 22 |
| REGN5381 + Placebo | Regeneron Pharmaceuticals | Phase 2 | 51 |
| SAL0140 + SAL0140 placebo | Shenzhen Salubris Pharmaceuticals | Phase 1 | 32 |